Results 281 to 290 of about 125,484 (349)

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well‐established exposure–response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy–
Amy Rieborn, Eline L. Giraud, Teun van Gelder, Hans Gelderblom, Nielka P. van Erp, Tom van der Hulle, Dirk Jan A. R. Moes   +6 more
wiley   +1 more source

Appropriate Use of Proton Pump Inhibitors in General Out Patient Department of a Tertiary Care Center of Kathmandu Valley: An Observational Study. [PDF]

JNMA J Nepal Med Assoc
Bhandari J, Bhandari N.
europepmc   +1 more source

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Pemetrexed is a cornerstone in chemo(immunotherapy) of non‐small cell lung cancer and mesothelioma; however, it is contraindicated in patients with renal impairment due to severe toxicity concerns. Therefore, a large proportion of patients is withheld from effective chemo(immunotherapy).
Nikki de Rouw, Leila‐Sophie Otten, Mart P. Kicken, Berber Piet, Bonne Biesma, Bianca van Veggel, Christi M.J. Steendam, Ben van den Borne, Lizza E.L. Hendriks, Sander Croes, Anne‐Marie C. Dingemans, Daphne W. Dumoulin, Ron H.J. Mathijssen, Jacobus A. Burgers, Alwin D.R. Huitema, Hieronymus J. Derijks, Maarten J. Deenen, Michel M. van den Heuvel, Rob ter Heine   +18 more
wiley   +1 more source

Practices and knowledge of community pharmacists towards the use of proton pump inhibitors: a cross-sectional study in Jordan. [PDF]

BMJ Open
Gharaibeh L, Alameri MA, Al-Hawamdeh MI, Daoud E, Atwan R, Lafi Z, Zakaraya ZZ.   +6 more
europepmc   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Association between <i>CYP2C19</i> polymorphism and proton pump inhibitors adverse drug reactions: a narrative review. [PDF]

Front Pharmacol
Ibrahim A, Yusuff K, Awaisu A, Elewa H.
europepmc   +1 more source

Learning Strategies from Nature's Blueprint to Cyclic Carbonate Synthesis

ChemSusChem, Volume 18, Issue 6, March 15, 2025.
The development of sustainable synthetic methods for cyclic carbonates draws inspiration from nature, focusing on eco‐friendly processes and renewable resources like CO2 and biomass. This review explore various CO2 activation mechanisms, green chemistry principles, and green catalysts.
Erika Saccullo, Vincenzo Patamia, Chiara Zagni, Antonio Rescifina, Giuseppe Floresta   +4 more
wiley   +1 more source

Association between proton pump inhibitors and dementia risk: a Mendelian randomization study. [PDF]

Sci Rep
Xie K, Li J, Tang C, Huang Z, Chen M.
europepmc   +1 more source

Analytical and Pharmacological Characterization of 1‐(Furan‐2‐Carbonyl)‐LSD (1F‐LSD) and Comparison With 1‐(Thiophene‐2‐Carbonyl)‐LSD (1T‐LSD)

Drug Testing and Analysis, EarlyView.
The novel lysergamide 1‐(furan‐2‐carbonyl)‐LSD (1F‐LSD) was analytically characterized. 1F‐LSD showed LSD‐like activity in vivo similar to 1‐(thiophene‐2‐carbonyl)‐LSD (1T‐LSD) used for comparison. Administration studies in mice and LC–MS analysis revealed that 1F‐LSD served as a prodrug.
Simon D. Brandt, Pierce V. Kavanagh, Sarah Gare, Simon P. Elliott, Alexander Stratford, Adam L. Halberstadt   +5 more
wiley   +1 more source

Deprescribing of proton pump inhibitors in older patients: A cost-effectiveness analysis. [PDF]

PLoS One
Xie M, You JHS.
europepmc   +1 more source